<DOC>
	<DOCNO>NCT01061541</DOCNO>
	<brief_summary>In order reduce amount thiomersal vaccine , GSK Biologicals develop DTPw-HBV vaccine low thiomersal content ( Tritanrix™- HepB low thio ) . This vaccine use combination Hib low dose vaccine contain 2.5µg PRP antigen ( Hib 2.5 ) . The purpose study generate clinical data Tritanrix™-HepB low thio vaccine extemporaneously mixed Hib 2.5 vaccine . The control group receive Tritanrix™-HepB/Hiberix™ . Subjects received primary vaccination study 208108/091 ( double blind ) . Of subject 50 % randomised participate PRP challenge study ( 208108/092 ) ( open ) , subject invite participate booster study DTPWHBV=HIB2.5-093 ( 101477 ) .</brief_summary>
	<brief_title>Immunogenicity , Safety &amp; Reactogenicity GSK Vaccine Tritanrix™-HepB/Hib2.5 Compared GSK Vaccine Tritanrix™-HepB/Hiberix™</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol enrol study . A male female , include , 6 8 week age time first vaccination . Written inform consent obtain parent guardian subject . Free obvious health problem establish medical history clinical examination enter study . Born gestation period 36 42 week . Born mother proven seronegative HBsAg . Planned administration/ administration vaccine foreseen study protocol within 30 day dose vaccine , exception oral polio vaccine ( OPV ) . Bacille CalmetteGuérin ( BCG ) vaccine receive first 2 week life . Use investigational nonregistered drug vaccine study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug since birth . Previous vaccination diphtheria , tetanus , pertussis , hepatitis B and/or Hib . History , intercurrent , diphtheria , tetanus , pertussis , hepatitis B and/or Hib disease . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine . Major congenital defect serious chronic illness . History neurologic disorder seizure . Acute disease time enrolment . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination history . Administration immunoglobulins and/or blood product since birth plan administration study period . Other condition opinion investigator may potentially interfere interpretation study outcome .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>8 Weeks</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Pertussis</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Hiberix™</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>DTPw-HBV vaccine</keyword>
	<keyword>Tritanrix™-HepB</keyword>
	<keyword>Haemophilus influenzae type b</keyword>
	<keyword>Diphtheria</keyword>
	<keyword>Hib vaccine</keyword>
</DOC>